

Gonçalves de Oliveira Ribeiro, Maria de Fátima Servidoni, Mônica Corso Pereira; Roberto José Negrão Nogueira.

## References

1. Collie JT, Massie RJ, Jones OH, LeGrys VA, Greaves RF. Sixty five years since the New York heat wave: advances in sweat testing for cystic fibrosis. *Pediatr Pulmonol.* 2014;49:106–17.
2. Traeger N, Shi Q, Dozor AJ. Relationship between sweat chloride, sodium, and age in clinically obtained samples. *J Cyst Fibros.* 2014;13:10–4.
3. Levy H, Farrell P. New challenges in the diagnosis and management of cystic fibrosis. *J Pediatr.* 2015;166:1337–40.
4. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. *J Pediatr.* 2008;153:54–14.
5. Vermeulen F, Le Camus C, Davies JC, Bilton D, Milenković D, De Boeck K. Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations. *J Cyst Fibros.* 2016 [Epub ahead of print].

A.G. Faria<sup>a,b,1</sup>,  
F.A.L. Marson<sup>a,b,c,\*1</sup>, A.F. Ribeiro<sup>a</sup>,  
J.D. Ribeiro<sup>a,b,1</sup>

<sup>a</sup> *Department of Pediatrics, Faculty of Medical Sciences, University of Campinas, Brazil*

<sup>b</sup> *Laboratory of Pulmonary Physiology, Center for Pediatrics Investigation, Faculty of Medical Sciences, University of Campinas, Brazil*

<sup>c</sup> *Department of Medical Genetics, Faculty of Medical Sciences, University of Campinas, Brazil*

\* Corresponding author.

E-mail address: [fernandolimamarson@hotmail.com](mailto:fernandolimamarson@hotmail.com) (F.A.L. Marson).

<sup>1</sup> Equally contributing authors.

<http://dx.doi.org/10.1016/j.rppnen.2016.11.001>  
2173-5115/

© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Survival analysis of patients with non-small cell lung cancer treated by surgery with curative intent



Dear Editor,

Lung cancer is the leading cause of cancer deaths in the entire world, representing 19.4%–27% of all deaths from cancer.<sup>1</sup> Surgical resection is considered the treatment standard for early stage disease (stage I and II) and for some cases in IIIA stage.<sup>1</sup> Accordingly to the TNM system, 5-years survival for IA, IB, IIA, IIB, IIIA, IIIB and IV stage disease, is about 73%, 58%, 46%, 36%, 24%, 9% and 13% respectively.<sup>2</sup>

The purpose of this study is to describe a population of patients submitted to curative intent surgery for lung cancer and analyze the survival.

Data was collected retrospectively from the clinical process of patients with NSCLC who had undergone pulmonary resection surgery with curative intent who were being followed at the Pneumological Oncology Service of a University Hospital. Patients who had not had lymphadenectomy were excluded.

After initial treatment was completed, patients were followed every 3 months with a complete physical examination, blood analyses and chest X-ray for 5 years, every 6 months with computed tomography (CT) for 2 years and then annually.

A descriptive analysis of the variables of 102 patients undergoing pulmonary resection surgery was carried out. This included patients who were operated on between 1 January 2008 and 31 December 2012 and were followed until 31 December 2015.

The comparison of the distribution of variables was made using adjustment tests (Binomial and Chi-square). Kaplan–Meier survival analysis was used to determine mean survival time and mortality rate according to the disease stage and comparison of these by log-rank test. The association between pathologic stage and survival was assessed using Fisher's exact test. The analysis was performed in the SPSS, version 23, and the statistical tests analyzed at the significance level of 5%.

The study was conducted with a group of 102 patients with an average age of  $63.69 \pm 9.31$ ; 68.6% were men. The distribution of tumor location is preferentially peripheral (72.5%), appearing in the lobar bronchus (15.7%) or main bronchus (11.8%) with less frequency ( $p < 0.001$ ). Most of the patients had Adenocarcinomas (61.8%) or squamous tumors (26.5%). Most of the surgeries performed were lobectomies (81.4%), followed by pneumonectomy (14.7%), wedge excision (2.9%) and segmentectomy (1%). 26.5% cases were in pathological stage IA, 24.5% in IB, 21.6% in IIA, 9.8% in IIB and 17.6% in IIIA ( $p = 0.064$ ).

Of the 102 cases analyzed, 41 died during the study period (40.2%). The estimated mortality rate in the population should be between 30.7% and 47.7%. The median overall survival time was  $65.61 \pm 3.56$  months and the 5-year survival (60 months) was  $46.20 \pm 1.93$  months. There was a statistically significant difference in mean survival time depending on the disease stage ( $p < 0.001$ ) [Fig. 1]. The tendency is that patients with stage IA have a better prognosis, with a statistically significant difference between this and any of the other stages. Table 1 presents the mean survival time observed at the 5-year follow-up, and the respective estimated mean survival time in the population, in relation to the disease stage. In the legend, the  $p$ -values adjusted for multiple comparisons of the survival time between pairs of stages evaluated are presented.




Fig. 1 Cumulative probability of 5-year survival by stage.

Table 1 5-Year survival (months) by stage.

Pathological stage	5-Year survival (months)			
	Mean	Standard error	Confidence interval 9(5%)	
			Inferior limit	Upper limit
IA <sup>a</sup>	58.70	1.27	56.21	61.20
IB <sup>b</sup>	51.73	2.80	46.25	57.21
IIA <sup>c</sup>	38.05	4.72	28.79	47.30
IIB <sup>d</sup>	40.20	6.92	26.63	53.77
IIIA	33.16	4.80	23.75	42.56
Overall	46.20	1.93	42.43	49.98

<sup>a</sup> Survival time was significantly longer than in the IB stages ( $p=0.006$ ), IIA ( $p<0.001$ ), IIB ( $p<0.001$ ) or IIIA ( $p<0.001$ ).

<sup>b</sup> Survival time significantly longer than stages IIA ( $p=0.031$ ) or IIIA ( $p=0.002$ ), and similar survival time at IIB ( $p=0.166$ ).

<sup>c</sup> Survival time similar to the stages IIB ( $p=0.868$ ) and IIIA ( $p=0.364$ ), without statistical significance.

<sup>d</sup> Survival time similar to stage IIIA ( $p=0.276$ ), without statistical significance.

Adenocarcinoma was the predominant histologic type, as in the international literature. (61.8%).<sup>3</sup> As expected, the majority of the tumors had a peripheral location, probably related to the predominance of adenocarcinomas.

The majority of our patients were treated with lobectomy plus systematic lymph node dissection, the standard treatment for lung cancer resections with curative intent.<sup>1</sup>

Our overall survival is much better ( $65.61 \pm 3.56$  months) than the 50 months found by Yue et al.<sup>4</sup> Our results are similar to those found by Liu et al.<sup>5</sup> for stage IA (89.9 versus 88.11 months) and much lower for stage IB (75.5 versus

87.07 months). Although the overall survival in months was encouraging compared to other studies, we found a 5-year survival rate of 58.5%, a lower value compared to the 64.1% found by Qiu et al.<sup>6</sup> These different results can be explained by the different inclusion and exclusion criteria used in the different studies.

We found a positive correlation between disease stage and 5-year survival that was 96.3%, 84.0%, 50%, 50% and 25.4% in stages IA, IB, IIA, IIB and IIIA respectively, slightly better results in than those reported by Dziedzic et al.<sup>2</sup>

Our study has some limitations that should be mentioned. We did not collect data about the number of lymph nodes

and which stations were excised or which treatment was performed on each patient, two risk factors that we know can predict mortality.

However, this is the first study to evaluate survival in our country and despite the retrospective nature of this study it is a real life study that gives us information about our population.

### Conflicts of interest

The authors have no conflicts of interest to declare.

### References

1. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. *Transl Lung Cancer Res.* 2014;3:242–9.
2. Dziedzic DA, Rudzinski P, Langfort R, Orłowski T. Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer. *Clin Lung Cancer.* 2016;17:157–67.
3. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2016;27 Suppl. 5:v1–27.
4. Yue D, Gong L, You J, Su Y, Zhang Z, Zhang Z, et al. Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines. *BMC Cancer.* 2014;14:422–30.
5. Liu CH, Peng YJ, Wang HH, Chen YC, Tsai CL, Chian CF, et al. Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients. *Thorac Cancer.* 2015;6:620–8.
6. Qiu C, Wang G, Xu J, Cui L, Dong W, Ni Y, et al. Sublobectomy versus lobectomy for stage I non-small cell lung cancer in the elderly. *Int J Surg.* 2016;37:1–7.

C. Cruz<sup>a,\*</sup>, M. Afonso<sup>a</sup>, B. Oliveiros<sup>b</sup>, A. Pêgo<sup>a</sup>

<sup>a</sup> *Pulmonology A Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal*

<sup>b</sup> *Laboratório de Bioestatística e Informática Médica def Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal*

\* Corresponding author.

E-mail address: [cristiana.rl.cruz@gmail.com](mailto:cristiana.rl.cruz@gmail.com) (C. Cruz).

<http://dx.doi.org/10.1016/j.rppnen.2017.03.003>  
2173-5115/

© 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).